TF and systemic lupus erythematosus: However, our study identifies a targetable pathway (the type I IFN-TF axis) in thromboinflammation and our work supports redeploying the clinically approved DMF in clinical trials for inflammation-associated coagulopathies, in particular for autoimmune and thromboinflammatory diseases including systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), which are characterized by excessive type I IFN production and are associated with significantly greater risk of developing thrombotic cardiovascular disease84,85.